TRIM11 for tauopathies; plus TCRs that recognize multiple antigens and more

Scientists from University of Pennsylvania including  Evergreen Therapeutics Inc. co-founder Xiaolu Yang reported in Science that TRIM11 levels are reduced in human postmortem brain samples from patients with Alzheimer’s disease, and that intracranial delivery of TRIM11 through adeno-associated viruses mitigated pathology, neuroinflammation and cognitive impairment in tauopathy mouse models.

The authors found TRIM11 regulates the Alzheimer’s drug target tau by three mechanisms: it promotes proteasomal degradation of tau, functions as a molecular chaperone to lessen the protein’s misfolding and aggregation, and dissolves preexisting tau deposits...